← Back to Screener
Celularity Inc. Class A Common Stock (CELU)
Price$1.24
Favorite Metrics
Price vs S&P 500 (26W)-48.75%
Price vs S&P 500 (4W)-8.67%
Market Capitalization$35.47M
All Metrics
Book Value / Share (Quarterly)$0.39
P/TBV (Annual)1.57x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)36.47%
Cash Flow / Share (Quarterly)$-0.29
Price vs S&P 500 (YTD)6.67%
Gross Margin (TTM)50.61%
Net Profit Margin (TTM)-198.75%
EPS (TTM)$-3.33
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-3.33
EPS (Annual)$-2.64
ROI (Annual)-113.87%
Gross Margin (Annual)72.36%
Cash / Share (Quarterly)$0.00
Revenue Growth QoQ (YoY)-43.16%
ROA (Last FY)-43.53%
Revenue Growth TTM (YoY)-15.81%
EBITD / Share (TTM)$-2.98
ROE (5Y Avg)-245.63%
Operating Margin (TTM)-141.01%
Cash Flow / Share (Annual)$-0.35
P/B Ratio4.01x
P/B Ratio (Quarterly)5.29x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.86x
Net Interest Coverage (TTM)-8.76x
ROA (TTM)-65.03%
EV / EBITDA (TTM)5.00x
EPS Incl Extra (Annual)$-2.64
Current Ratio (Annual)0.39x
Quick Ratio (Quarterly)0.11x
3-Month Avg Trading Volume0.13M
52-Week Price Return-25.00%
EV / Free Cash Flow (Annual)3.50x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.34
P/S Ratio (Annual)0.65x
Asset Turnover (Annual)0.41x
52-Week High$4.35
EPS Excl Extra (Annual)$-2.64
26-Week Price Return-40.00%
Quick Ratio (Annual)0.28x
13-Week Price Return-7.52%
Total Debt / Equity (Annual)4.75x
Current Ratio (Quarterly)0.16x
Enterprise Value$75.307
Asset Turnover (TTM)0.33x
Book Value / Share Growth (5Y)-57.40%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.69x
Pretax Margin (Annual)-106.77%
Cash / Share (Annual)$0.03
3-Month Return Std Dev66.70%
Net Income / Employee (TTM)$-1
ROE (Last FY)-654.89%
Net Interest Coverage (Annual)-9.91x
EPS Basic Excl Extra (Annual)$-2.64
Receivables Turnover (TTM)5.24x
Total Debt / Equity (Quarterly)4.79x
EPS Incl Extra (TTM)$-3.33
Receivables Turnover (Annual)2.57x
ROI (TTM)-92.04%
P/S Ratio (TTM)0.87x
Revenue / Share (Annual)$2.48
Tangible BV / Share (Annual)$1.58
Price vs S&P 500 (52W)-60.09%
Year-to-Date Return10.81%
5-Day Price Return-3.91%
EPS Normalized (Annual)$-2.64
ROA (5Y Avg)-40.28%
Net Profit Margin (Annual)-106.77%
Month-to-Date Return-7.52%
Cash Flow / Share (TTM)$-0.44
EBITD / Share (Annual)$-2.29
Operating Margin (Annual)-77.95%
ROI (5Y Avg)-86.18%
LT Debt / Equity (Quarterly)4.07x
EPS Basic Excl Extra (TTM)$-3.33
P/TBV (Quarterly)8.85x
P/B Ratio (Annual)5.20x
Inventory Turnover (TTM)6.15x
Pretax Margin (TTM)-198.75%
Book Value / Share (Annual)$0.39
Price vs S&P 500 (13W)-10.38%
Beta0.68x
Revenue / Share (TTM)$1.54
ROE (TTM)-272.44%
52-Week Low$1.01
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CELUCelularity Inc. Class A Common Stock | 0.87x | -15.81% | 50.61% | — | $1.24 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Celularity is a clinical-stage biotechnology company developing placental-derived cell therapies for cancer, immunological, infectious, and degenerative diseases. Its pipeline includes natural killer cells, engineered T cells (including CAR-T), and mesenchymal stromal cells. The company operates three business segments—Cell Therapy, Degenerative Disease, and Bio-banking—with the bio-banking division currently serving as the primary revenue source.